Skip to content
Clinical Trials – home

Spitalul de Pneumologie Dr. Lavinia Davidescu S.R.L

Verified siteinfo

Romania Strada Doja Gheorghe No. 1a, 410155 Oradea, Romania

  • 4 trials recruiting
  • Chronic obstructive pulmonary disease · Idiopathic pulmonary fibrosis · Asthma
  • Adults and children

About Specializations

Spitalul de Pneumologie Dr. Lavinia Davidescu S.R.L in Oradea, Romania specialises in clinical trials of conditions such as Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Asthma, and other specialisations. This site conducts important research.

Main research areas of the site

Chronic Obstructive Pulmonary Disease (COPD)

The Spitalul de Pneumologie Dr. Lavinia Davidescu S.R.L conducts focused research on COPD, aiming to test new inhaled therapies, assess long‑term safety, and reduce the frequency of moderate‑to‑severe exacerbations that limit patients’ daily lives.

  • Inhaled corticosteroid/long‑acting bronchodilator combination studies
  • Evaluation of novel anti‑inflammatory agents
  • Long‑term safety monitoring in chronic disease
  • Strategies to lower exacerbation rates
  • Comparative effectiveness of triple therapy regimens

With 12 clinical trials completed, the site contributes valuable data on improving lung function and quality of life for COPD patients across Europe.

Asthma (Mild to Moderate and Severe Uncontrolled)

Research at the Oradea center explores both routine and advanced treatments for asthma, from optimizing standard inhaler combinations to evaluating biologic adjuncts for severe uncontrolled disease, with the goal of enhancing airway control and preventing attacks.

  • Step‑up therapy for mild‑to‑moderate asthma
  • Biologic therapies as adjuncts in severe uncontrolled asthma
  • Therapeutic equivalence of new inhaler devices
  • Real‑world effectiveness of combination inhalers
  • Pediatric and adolescent asthma management studies

The trials aim to improve forced expiratory volume outcomes and reduce reliance on rescue medication, offering new options for patients of all ages.

Idiopathic Pulmonary Fibrosis (IPF)

The facility’s IPF program evaluates promising anti‑fibrotic compounds, focusing on safety, tolerability, and the potential to slow disease progression while preserving lung capacity in a condition with few effective treatments.

  • Development of novel anti‑fibrotic agents
  • Long‑term safety assessments in progressive lung disease
  • Biomarker analysis for disease activity
  • Combination therapy strategies
  • Quality‑of‑life outcome measurements

By generating robust clinical data, the site supports advances that could extend survival and improve daily functioning for individuals with idiopathic pulmonary fibrosis.

Respiratory Tract Disease Research

Across its portfolio, Spitalul de Pneumologie Dr. Lavinia Davidescu S.R.L addresses a range of chronic respiratory conditions, integrating patient‑focused endpoints with cutting‑edge therapeutic evaluation to enhance overall respiratory health.

  • Integrated management of chronic respiratory diseases
  • Multicenter collaboration throughout Europe
  • Patient‑reported outcome measures
  • Advanced pulmonary function testing
  • Translational research linking biomarkers to treatment response

The site’s 12 trials, led by a dedicated investigator, contribute essential evidence for the development of safer and more effective treatments for respiratory tract diseases.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Strada Doja Gheorghe No. 1a410155 OradeaRomania
Recruiting now
4 trials
Conditions studied
3
Partner status
Verified site

More sites in OradeaRomania

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

15 clinical trials

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Asthma

Recruiting

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Generate Biomedicines Inc.

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Puretech Lyt 100 Inc.

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Zampilimab
  • Sponsor:Chiesi Farmaceutici S.p.A.

Asthma

Not recruiting

Study on the Effectiveness and Safety of Fluticasone Propionate and Salbutamol Sulfate for Asthma in Patients Aged 12 and Older

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Study on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Tanimilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Roflumilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Study on the Effectiveness and Safety of CHF 5993 Compared to CHF 1535 for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate Anhydrous
  • Sponsor:Chiesi Farmaceutici S.p.A.

Asthma

Not recruiting

Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Chiesi Farmaceutici S.p.A.

Study on the Effects of Itepekimab in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.